Skip to content

The Role of Calcipotriol as Radioprotector of Skin

Phase 2 Study of the Role of Calcipotriol as Radioprotector of Skin in Women Receiving Radiotherapy Treatment to the Breast.

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00445250
Enrollment
50
Registered
2007-03-08
Start date
Unknown
Completion date
Unknown
Last updated
2007-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiodermatitis

Keywords

Calcipotriol, Breast, Cancer, Radiotherapy, Radiodermatitis in Breast Cancer

Brief summary

Examining the hypothesis that protecting keratinocytes by calcipotriol can prevent in-vivo cutaneous side effect in patients receiving radiotherapy to the breast. To check the connection between the skin effect of radiotherapy and different parameters including diseases such as diabetes and lupus, use of medications, allergies, weight, habits, size of the irradiated breast, previous chemotherapy treatment and exposure to sunlight.

Detailed description

STUDY PROTOCOL Fifty women diagnosed with breast cancer planned to receive adjuvant radiotherapy, will participate in the study. About 15 minutes after receiving the daily radiation dose fraction, a cream containing an active vitamin D analogue will be applied to half of the breast with inspection of a nurse. The other half of the breast will have a standard cream applied . During the days that radiotherapy is not administered the standard cream will be applied to both halves of the breast in a case of strong reaction to radiotherapy (e.g. strong erythema, painful tenderness etc.)The adverse skin effects will be assessed according to the following criteria: 1. . an assessment by a physician and a nurse according to the RTOG score (6). As follows: Grade 0 - no reaction. Grade 1 - light erythema dry peeling, decrease in sweat production. Grade 3 - extensive moist peeling, pitting edema. Grade 4 - ulcers, bleeding and necrosis. 2. . A questionnaire to each patient regarding the efficacy and safety of the cream. 3. . Number of interruption of radiotherapy treatment. The assessment will be done each week during radiotherapy treatment and weekly for three weeks following the completion of radiotherapy treatment. Safety report will be sent to the local independent ethics committee after the examination of the first ten patients. The protective effect of the cream containing calcipotriol will be compared to the standard treatment and analyzed statistically using the parameters mention above. The relation between the background disease, medications, allergies, weight, habits, size of the irradiated breast, sun exposure, previous chemotherapy treatment and exposure to sunlight and the skin reaction will be evaluated. INCLUSION CRITERIA 1. . Age ranging from 18 to 75. 2. . Confirmed histological diagnosis of Breast cancer. 3. . Radiotherapy treatment to the breast following lumpectomy. EXCLUSION CRITERIA 1. . Scleroderma. 2. . An extremely large breast. Interfiled above 25 cm. 3. . Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is not a contraindication. 4. . Mastectomy.

Interventions

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Age ranging from 18 to 75. 2. Confirmed histological diagnosis of Breast cancer. 3. Radiotherapy treatment to the breast following lumpectomy.

Exclusion criteria

1. Scleroderma. 2. An extremely large breast. Interfiled above 25 cm. 3. Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is not a contraindication. 4. Mastectomy.

Design outcomes

Primary

MeasureTime frame
Prevention of radiodermatitis

Secondary

MeasureTime frame
Side effects of Calcipotriol

Countries

Israel

Contacts

Primary ContactEyal Fenig, M.D.
efenig@clalit.org.il97239377964
Backup ContactOfer Purim, M.D.
oferp@clalit.org.il97239377973

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026